Open AccessStudy of hypoglycemic activity of tablets of “Gliphasonorm” capsules and “Gliphasolin” on the model of streptozotocin-induced diabetes in rats
Author(s) -
В. А. Рыбак,
Л. М. Малоштан
Publication year - 2015
Publication title -
medična ì klìnìčna himiâ
Language(s) - English
Resource type - Journals
eISSN - 2414-9934
pISSN - 2410-681X
DOI - 10.11603/mcch.2410-681x.2015.v17.i3.5045
Subject(s) - metformin , streptozotocin , hemoglobin , diabetes mellitus , medicine , endocrinology , pharmacology , chemistry
The conducted research allowed to determine that the tablets “Gliphasonorm” capsules and “Gliphasolin” in an experimental model of streptozotocin-induced diabetes significantly reduced the level of glycosylated hemoglobin, decreased with the level of glucose in the blood of animals compared to diabetic control. After 14 days of the study capsules “Gliphasolin” showed a more pronounced hypoglycemic activity (4.4 % and 8.0 % greater) than tablets “Gliphasonorm” and the reference drug metformin. Under the action caps “Gliphasolin” on the 12th day of the study showed marked reduction of glycosylated hemoglobin in the blood of animals (3.1 % and 5.6 % greater) than that of the tablets of “Gliphasonorm” and metformin. Capsules “Gliphasolin” and tablets “Gliphasonorm” based bioflavonoid complex from beans are promising in the therapy of diabetes type 2 on the background of obesity and reduce the risk of micro- and macroangiopathies.